Skip to content Skip to navigation

ViroPharma Merger Review: Is $50.00 a Fair Price?

ViroPharma Merger Review:  Is $50.00 a Fair Price?

Are ViroPharma shareholders getting a fair deal in announced buyout by Shire? 

The board of directors of ViroPharma (VPHM) entered into a definative merger agreement pursuant to which it is being acquired by Shire Plc.  The ViroPharma merger values the company at approximately $4.2 billion.  Under the terms of the agreement, public shareholders of ViroPharma will receive $50.00 per share in cash for each share of ViroPharma they own. 

ViroPharma takeover raises an obvious question:  Is this the best the VPHM board could do?

If you own the common stock of ViroPharma and are concerned about the transaction and would like to learn more about how to begin a cost free corporate review of this merger, please fill out the contact form on this web page or call Attorney George Pressly at 1-(800)-631-6234.

ViroPharma board of directors owe VPHM shareholders specific duties when selling the company

  • Is $50.00 per share a fair price for VPHM shareholders? 
  • Does the merger agreement contain an unfair termination provision?  
  • Does the merger agreement limit the ability of ViroPharma to obtain additional suitors or to accept additional proposals?
  • Did the ViroPharma board of directors obtain an appraisal from an independent investment bank?
  • What did the independent appraisal show?  
  • Did the board of directors engage other potential suitors?
  • Will the proxy statement contain accurate and complete disclosures about future executive compensation packages?

ViroPharma (VPHM) merger or takeover shareholder lawsuit investigation

State security laws provide shareholders a no cost means to question a proposed sale of a publicly traded company.  This review process is deemed a shareholder class action and affords at times shareholders an avenue to investigate fully the proposed transaction.  At minimum, this process often obtains answers to the above questions.  If you own the common stock of ViroPharma and if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please fill out the contact form on this web page.